Insulet Co. (NASDAQ:PODD) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Insulet Co. (NASDAQ:PODD - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $267.44.

Several research analysts have recently issued reports on PODD shares. JPMorgan Chase & Co. raised their price objective on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Citigroup boosted their price objective on Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Raymond James upped their price target on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Finally, BTIG Research increased their target price on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the company's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.47% of the company's stock.

Hedge Funds Weigh In On Insulet

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Insulet by 36.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 2,351 shares of the medical instruments supplier's stock valued at $474,000 after acquiring an additional 625 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Insulet by 90.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,797 shares of the medical instruments supplier's stock worth $766,000 after buying an additional 1,800 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Insulet by 13.5% in the 2nd quarter. Fifth Third Bancorp now owns 8,221 shares of the medical instruments supplier's stock valued at $1,659,000 after buying an additional 975 shares in the last quarter. 1620 Investment Advisors Inc. purchased a new position in shares of Insulet in the 2nd quarter valued at $52,000. Finally, New York State Teachers Retirement System raised its stake in Insulet by 2.3% during the 2nd quarter. New York State Teachers Retirement System now owns 63,478 shares of the medical instruments supplier's stock worth $12,810,000 after acquiring an additional 1,400 shares in the last quarter.

Insulet Stock Up 0.0 %

Shares of PODD stock traded up $0.12 during trading hours on Thursday, reaching $256.56. 676,983 shares of the company's stock were exchanged, compared to its average volume of 760,717. The stock has a market cap of $18.00 billion, a PE ratio of 43.93, a PEG ratio of 4.12 and a beta of 1.21. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock's fifty day moving average price is $253.81 and its two-hundred day moving average price is $222.37. Insulet has a 1 year low of $160.19 and a 1 year high of $279.77.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.